Menu

World’s First Commercial iPSC Cell Plant Opens in Japan

The $340 million, 30,000-square-foot center will produce cells for therapeutic applications.

Mar 23, 2018
Jim Daley

Human induced pluripotent stem cellsCHRISTINE HALE, WIKIMEDIAA pharmaceutical company based in Osaka, Japan, opened a regenerative medicine center yesterday (March 22) that will produce cells derived from induced pluripotent stem (iPS) cells for commercial applications. The center is the first plant of its kind globally. It will initially produce cells for use in clinical trials.

The Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy will allow the company to “gain an overwhelming advantage in the market of medical and pharmaceutical products,” Masayo Tada, president of Sumitomo Dainippon Pharma, tells The Asahi Shimbun. “We will occupy a definite position in the field of regenerative medicine.” On April 1, Hiroshi Nomura, currently the company’s executive vice president, will replace Tada as president, according to The Pharma Letter. Tada will transition to the position of chairman.

Existing iPSC production facilities, including the National Institutes of Health’s Center for Regenerative Medicine and WiCell’s Stem Cell Bank, have made cells available to researchers. The Sumitomo Dainippon plant will be the first to offer cells for commercial purposes.

Construction of the center cost approximately 3.6 billion yen ($342.7 million USD), according to a statement. The facility has more than 30,000 square feet of floor space divided among three autonomous zones that will produce different types of cells. Company officials say that each zone will be able to produce enough cells to treat hundreds of patients per year, according to The Asahi Shimbun

The company will use iPS cells produced at Kyoto University’s Center for iPS Cell Research and Application (CiRA) for cell production. Sumitomo Dainippon and CiRA have previously collaborated to develop iPS cell-based regenerative medicine technology for patients with Parkinson's disease.

See “Banking on iPSCs

Sumitomo Dainippon plans to make regenerative medicine one of its core businesses and endeavors to increase sales to 200 billion yen ($1.8 billion USD) by 2030, according to The Asahi Shimbun.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing